KTTA PASITHEA THERAPEUTICS CORP

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Pasithea’s Chairman, Prof. Lawrence Steinman, to be Awarded Honorary Doctorate by University of Buenos Aires

MIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will present preclinical proof of concept study results of the Company’s tolerizing vaccine program in multiple sclerosis, PAS002, on Oct. 14-17, 2022, at the Immunotherapy 2022 International Course and Symposium in Buenos Aires, Argentina. PAS002 is a proprietary DNA vaccine construct encoding GlialCAM.

During the Symposium, Prof. Lawrence Steinman and Dr. James Allison, recipient of the 2018 Nobel Prize in Medicine, will each be awarded an honorary doctorate by the University of Buenos Aires. Other speakers will include Dr. Laurie Glimcher, President and CEO of the Dana-Farber Cancer Institute in Boston, and Prof. Ignacio Melero, Co-Director of the Department of Immunology and Immunotherapy at the University of Navarra in Spain.

“We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy,” said Dr. Tiago Reis Marques, CEO, Pasithea. “The study results support the Company’s ongoing commitment to the program and move us further along in our mission to uncover new and effective treatments for neurological disorders.”

“It is an honor to be recognized alongside Dr. Allison by the University of Buenos Aires, an institution that promotes research and excellence,” added Prof. Steinman. “The field of neurology, particularly for disabling diseases such as MS, requires deep research into the nature of effective therapeutic and immunization solutions. I have dedicated my career to propelling these therapies forward for the thousands of people suffering from neurological diseases around the world.”

About Pasithea Therapeutics Corp.

Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome.

ABOUT PAS002

PAS002 is an engineered DNA plasmid designed to tolerize the immune system to GlialCAM.

About Multiple Sclerosis

Multiple Sclerosis (“MS”) is a chronic and potentially disabling autoimmune disease, and the most common neurodegenerative disease of the central nervous system in young adults. The pathological hallmark of MS is the formation of demyelinating lesions in the brain and spinal cord, with the immune system attacking the myelin sheath that normally protects nerve fibers in the brain, spinal cord, and optic nerve. There are now 2.8 million people worldwide who have MS, and every five minutes, someone, somewhere in the world is diagnosed with this disorder. While there is no way to predict with any certainty how an individual’s disease will progress, four basic MS disease courses (also called types or phenotypes) have been defined: clinically isolated syndrome, relapsing remitting, secondary progressive and primary progressive. The most common affecting around 85 per cent of everyone diagnosed with MS is relapsing remitting MS (RRMS). It means that symptoms appear (a relapse), and then fade away, either partially or completely (remitting).

Forward Looking Statements

This press release contains statements that constitute “forward-looking statements.” Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Company Contact

Dr. Tiago Reis Marques

Chief Executive Officer

E:

Investor Relations Contact

Lisa M. Wilson

In-Site Communications, Inc.

T: 212-452-2793

E:

Media Contacts

KCSA Strategic Communications

Raquel Cona / Shana Marino

E:



EN
17/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PASITHEA THERAPEUTICS CORP

 PRESS RELEASE

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Dise...

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD) MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ET...

 PRESS RELEASE

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase...

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 -- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines of therapy, including a prior MEK inhibitor + BRAF inhibitor combination therapy, achieves over 5 months of stable disease with tumor volume reduction of -14.9% and remains on treatment -- -- PAS-004 pharmacokinet...

 PRESS RELEASE

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 In...

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases -- Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases – -- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway – -- Study conducted at Francis Crick Institute by lead author of 2024 N...

 PRESS RELEASE

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-...

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site -- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas ---- Starting dose of 4mg tablet QD (once daily) ---- First trial site in Australia. Four additional sites planned for Australia, South Korea, and U.S. –-- Australian R&D Tax Incentive refund of up to 48.5% of eligible study-related cos...

 PRESS RELEASE

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics Announces Closing of $5 Million Public Offering Additional Gross Proceeds of Approximately $1.3 Million Received Upon Exercise of Certain Warrants Issued in the Public Offering MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the closing of its previously announced public offering of 3,571,428 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch